Metzger K H
Fortschr Med. 1978 Apr 13;96(14):779-82.
Within the framework of a clinical study in 30 female patients suffering from concealed and manifest iron deficiency, Tardyferon--a progressive iron preparation based upon two synergistic active principles--demonstrated its superiority especially with regard to its excellent tolerance which is so important in the treatment of such disorders. Apart from the depot effect ensuring an optimal absorption rate, the mucoproteose which promotes bioavailability by protecting the mucosa against iron-related irritation deserves great attention.
在一项针对30名患有隐匿性和显性缺铁性贫血的女性患者的临床研究框架内,Tardyferon(一种基于两种协同活性成分的新型铁制剂)尤其在耐受性方面展现出优势,而耐受性在这类疾病的治疗中至关重要。除了能确保最佳吸收率的长效作用外,通过保护黏膜免受铁相关刺激来促进生物利用度的黏蛋白聚糖也值得高度关注。